Royal Brompton Hospital, London, UK.
Personalized Medicine Asthma and Allergy Center, Humanitas University and Research Hospital, Milan, Italy.
Adv Ther. 2018 Oct;35(10):1485-1496. doi: 10.1007/s12325-018-0777-y. Epub 2018 Sep 4.
Severe asthma is a subtype of asthma that is difficult to treat and control. By conservative estimates, severe asthma affects approximately 5-10% of patients with asthma worldwide. Severe asthma impairs patients' health-related quality of life, and patients are at risk of life-threatening asthma attacks. Severe asthma also accounts for the majority of health care expenditures associated with asthma. Guidelines recommend that patients with severe asthma be referred to a specialist respiratory team for correct diagnosis and expert management. This is particularly important to ensure that they have access to newly available biologic treatments. However, many patients with severe asthma can suffer multiple asthma attacks and wait several years before they are referred for specialist care. As global patient advocates, we believe it is essential to raise awareness and understanding for patients, caregivers, health care professionals, and the public about the substantial impact of severe asthma and to create opportunities for improving patient care. Patients should be empowered to live a life free of symptoms and the adverse effects of traditional medications (e.g., oral corticosteroids), reducing hospital visits and emergency care, the loss of school and work days, and the constraints placed on their daily lives. Here we provide a Patient Charter for severe asthma, consisting of six core principles, to mobilize national governments, health care providers, payer policymakers, lung health industry partners, and patients/caregivers to address the unmet need and burden in severe asthma and ultimately work together to deliver meaningful improvements in care.
AstraZeneca.
严重哮喘是一种难以治疗和控制的哮喘类型。据保守估计，严重哮喘影响全球约 5-10%的哮喘患者。严重哮喘会损害患者的健康相关生活质量，使患者有发生危及生命的哮喘发作的风险。严重哮喘也占与哮喘相关的大部分医疗保健支出。指南建议将严重哮喘患者转介给专门的呼吸团队进行正确诊断和专家管理。这一点尤其重要，以确保他们能够获得新的可用生物治疗方法。然而，许多严重哮喘患者可能会多次发作哮喘，在被转介接受专科护理之前需要等待数年。作为全球患者倡导者，我们认为，提高对严重哮喘的实质性影响的认识和理解，为患者、护理人员、医疗保健专业人员和公众创造改善患者护理的机会，至关重要。患者应该有能力过上没有症状和传统药物（如口服皮质类固醇）不良反应的生活，减少住院和急诊治疗，减少上学和工作天数，并减轻日常生活的限制。在这里，我们提供了一份严重哮喘患者宪章，其中包含六个核心原则，以动员各国政府、医疗保健提供者、支付方政策制定者、肺部健康行业合作伙伴以及患者/护理人员来解决严重哮喘的未满足需求和负担，并最终共同努力，为护理提供有意义的改善。
阿斯利康。
